| Scientific Program | ||
| Stream 1 | Stream 2 | Stream 3 |
Stream 2: Frontiers of Immuno-Oncology
| Session 2-1: Immuno-Oncology Emerging Target and Biomarker | |
|
Day 1: Afternoon, Friday, October 11, 2019 Place: Room 617, 6th Floor, Dalian International Conference Center |
|
| Chair: Dr. Adel K. El-Naggar, Professor, The University of Texas MD Anderson Cancer Center, USA | |
| Co-Chair: Dr. Longqin Hu, Professor and Chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, The State University of New Jersey, USA | |
|
Time
|
Speeches and Speakers |
|
13:30-13:35
|
Chair's Introduction |
| 13:35-14:00 | Title: C2-symmetric Small Molecule Inhibitors of PD-1/PD-L1 Protein-protein Interactions as Potential Immunotherapeuitcs Dr. Longqin Hu, Professor and Chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, The State University of New Jersey, USA |
|
14:00-14:25
|
Title: Biomarker Guided Targeted Therapy of Patients with Salivary Gland Carcinomas
Dr. Adel K. El-Naggar, Professor, The University of Texas MD Anderson Cancer Center, USA |
|
14:25-14:50
|
Title: The Pathological Role of YKL-40 in Cancer and Development of a Humanized Antibody against YKL-40
Dr. Rong Shao, Professor, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China |
|
14:50-15:15
|
Title: Companion Diagnostics for Trastuzumab-based Neoadjuvant Therapy - Two is Better than One Dr. Lim Yoon Pin, Assistant Professor, National University of Singapore, Singapore |
|
15:15-15:30
|
Coffee Break |
| 15:30-15:55 | Title: Targeting STAT3 in Glioblastoma Dr. Xiaohong Shu, Professor, Dalian Medical University, China |
|
15:55-16:20
|
Title: Globo Series Glycosphingolipids, Globo H and SSEA4, Serve as Promising Targets for Cancer Immunotherapy
Dr. Jiann-Shiun Lai, Vice President, Research, OBI Pharma, Inc., Taiwan |
| 16:20-16:45 | Speech Opportunity Available
Abstract and Biography: Submit Here |
| Session 2-2: Immuno-Oncology Precision Medicine | |
|
Day 1: Afternoon, Friday, October 11, 2019 Place: Room 618, 6th Floor, Dalian International Conference Center |
|
| Chair: Dr. Kangla Tsung (Zong), Founder, TAN-LUN Research Institute for Clinical Management of Cancer, China | |
|
Time
|
Speeches and Speakers |
|
13:30-13:35
|
Chair's Introduction |
|
13:35-13:55
|
Keynote Speech Title: Immunity-based, Individualized Approach to Clinical Management of Cancer Dr. Kangla Tsung (Zong), Founder, TAN-LUN Research Institute for Clinical Management of Cancer, China |
|
13:55-14:15
|
Title: Tumor Infiltrating Lymphocytes in Triple Negative Breast Carcinoma - An Update Dr. Shikha Bose, Clinical Professor, Cedars-Sinai Medical Center & David Geffen School of Medicine, University of California, Los Angeles, USA |
|
14:15-14:35
|
Title: Personalized Immuno-oncology Dr. Kewal K. Jain, CEO, Jain PharmaBiotech, Switzerland |
|
14:35-14:55
|
Title: NHEJ in cGAS-STING Pathway Dr. Weifeng Mao, Associate Professor, Dalian Medical University, China |
| 14:55-15:15 | Title: Abrogation of Phosphatidylserine-associated Immunosuppression for Brain Tumor Immunotherapy Dr. Xiaoyang Qi, Professor, University of Cincinnati, USA |
|
15:15-15:30
|
Coffee Break |
| Session 2-3: IO Antibodies, Vaccines and Combination Immunotherapy |
|
|
Day 2: Morning, Saturday, October 12, 2019 Place: Room 618, 6th Floor, Dalian International Conference Center |
|
| Chair: Dr. Zong Sheng Guo, Associate Professor, University of Pittsburgh Cancer Institute, University of Pittsburgh, USA | |
|
Time
|
Speeches and Speakers |
|
08:30-08:35
|
Chair's Introduction |
| 08:35-09:00 |
Keynote Speech Title: Immuo-Oncology Clinical Trials: Where We are and Where We Need to Go |
|
09:00-09:25
|
Title: Cancer Immunotherapy with Oncolytic Viruses: Arming with Th1-cytokines and Combining with Immune Checkpoint Blockade to Greatly Improve Therapeutic Efficacy |
| 09:25-09:50 |
Title: Expression of a Functional TCR CAR in Non T Cells Dr. Even Walseng, Staff Scientist, National Cancer Institute, National Institutes of Health, USA |
| 09:50-10:15 |
Title: Oncolytic Reovirus based Combination Anti-tumor Strategy |
| 10:15-10:30 | Coffee Break |
| 10:30-10:55 |
Title: Sensitizing Mature B Cell Lymphomas to Cancer Immunotherapy Dr. Jing Hong Wang, Associate Professor, Department of Immunology and Microbiology, University of Colorado, USA |
| 10:55-11:20 | Title: The Use of BOIN Design in Practice: What We Have Learned Dr. Suyu Liu, Assistant Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, USA |
|
11:20-11:45
|
Speech Opportunity Available Abstract and Biography: Submit Here |
| Session 2-4: Targeted Cancer Immunotherapy | |
|
Day 2: Afternoon, Saturday, October 12, 2019 Place: Room 618, 6th Floor, Dalian International Conference Center |
|
|
Chair: Dr. Haiyan Jia, Head of Growth Factors and Related Biologics, National Institute for Biological Standards and Control, UK |
|
| Co-Chair: Dr. Henry Yang, Associate Professor, Cancer Science Institute of Singapore, National University of Singapore, Singapore | |
|
Time
|
Speeches and Speakers |
|
13:30-13:35
|
Chair's Introduction |
| 13:35-14:00 |
Keynote Speech Title: Inorganic Adjuvants for Cancer Immunotherapy Dr. Xiupeng Wang, Senior Researcher, National Institute of Advanced Industrial Science and Technology (AIST), Japan |
| 14:55-14:25 | Title: Dual Nuclear Receptor Modulator for the Treatment of Prostate Cancer Dr. Mukesh K. Agarwal, President, MiRx Pharmaceuticals Ltd, USA |
| 14:25-14:50 | Title: Impact of Anti-VEGF Therapy on the Immune Response of Primary Human Vascular Endothelial Cells Dr. Haiyan Jia, Head of Growth Factors and Related Biologics, National Institute for Biological Standards and Control, UK |
| 14:50-15:15 | Title: Role of Anesthesia in Radiation Therapy Dr. Bharathi Gourkanti, Assistant Professor, Cooper Medical School of Rowan University, USA |
|
15:15-15:30
|
Coffee Break |
| 15:30-15:55 | Title: PD-L1 Expression and Targeted Immunotherapy Dr. Wenyi Gu, Research Fellow, The University of Queensland, Australia |
| 15:55-16:20 | Title: 10x Genomics Solutions for High Throughput Immune Profiling at Single-cell Resolution Dr. Joseph Aman, FAS Manager APAC, 10x Genomics, Inc, USA |
| 16:20-16:45 | Title: Engineered DNA Nanomedicines for Targeted Treatment of Colorectal Cancer via Apoptosis and Autophagy Dr. Nan Zhang, Associate Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, China |
| 16:45-17:10 | Title: Immunotherapies with Novel Neoantigens Derived from Intronic Polyadenylation and Retained Introns Dr. Henry Yang, Associate Professor, Cancer Science Institute of Singapore, National University of Singapore, Singapore |
| ©2016-2020 All right reserved by BIT Congress Inc. Tel: 0086-411-84799609, Fax: 0086-411-84796897 |
